Healthcare provider profile · identity verified

Mark E Collins, MD

Allopathic & Osteopathic Physicians|Family Medicine · ELK GROVE VILLAGE, IL · NPI 1508894882

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mark E Collins, MD received $81.56 in general payments during 2025 across 4 reported records.

Boston Scientific Corporation accounted for 55.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$81.56

4 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boston Scientific Corporation	Unresolved — no canonical attribution shown	$45.04	55.2%	2	2025
Salix Pharmaceuticals, a division of Bausch Health US, LLC	Unresolved — no canonical attribution shown	$21.50	26.4%	1	2025
Kowa Pharmaceuticals America, Inc.	Unresolved — no canonical attribution shown	$15.02	18.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$81.56	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
WATCHMAN FLX Normalized: watchman flx	Device	Boston Scientific Corporation	$45.04	2	2025
Source payment records 2025-09-18 · Boston Scientific Corporation · $22.52 · Open Payments source 2025-09-18 · Boston Scientific Corporation · $22.52 · Open Payments source
XIFAXAN Normalized: xifaxan	Drug	Salix Pharmaceuticals, a division of Bausch Health US, LLC	$21.50	1	2025
Source payment records 2025-10-13 · Salix Pharmaceuticals, a division of Bausch Health US, LLC · $21.50 · Open Payments source
ZORYVE Normalized: zoryve	Drug	Kowa Pharmaceuticals America, Inc.	$15.02	1	2025
Source payment records 2025-07-07 · Kowa Pharmaceuticals America, Inc. · $15.02 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	753	193
Atorvastatin Calcium	Atorvastatin Calcium	712	205
Amlodipine Besylate	Amlodipine Besylate	466	128
Lisinopril	Lisinopril	401	115
Alprazolam	Alprazolam	274	65
Vitamin D2	Ergocalciferol (Vitamin D2)	271	99
Pravastatin Sodium	Pravastatin Sodium	267	78
Alendronate Sodium	Alendronate Sodium	257	71
Metoprolol Succinate	Metoprolol Succinate	253	68
Pantoprazole Sodium	Pantoprazole Sodium	249	76
Losartan Potassium	Losartan Potassium	241	67
Hydrochlorothiazide	Hydrochlorothiazide	234	72
Omeprazole	Omeprazole	232	66
Allopurinol	Allopurinol	230	54
Meloxicam	Meloxicam	216	55
Tramadol Hcl	Tramadol Hcl	210	43
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	209	61
Rosuvastatin Calcium	Rosuvastatin Calcium	196	63
Zolpidem Tartrate	Zolpidem Tartrate	186	31
Metformin Hcl	Metformin Hcl	179	53
Escitalopram Oxalate	Escitalopram Oxalate	173	48
Metoprolol Tartrate	Metoprolol Tartrate	157	40
Jardiance	Empagliflozin	139	38
Potassium Chloride	Potassium Chloride	131	37
Gabapentin	Gabapentin	129	37
Tamsulosin Hcl	Tamsulosin Hcl	127	40
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	126	32
Simvastatin	Simvastatin	121	29
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	118	35
Furosemide	Furosemide	100	33
Metformin Hcl Er	Metformin Hcl	100	29
Carvedilol	Carvedilol	95	28
Duloxetine Hcl	Duloxetine Hcl	92	30
Azithromycin	Azithromycin	89	82
Eliquis	Apixaban	89	21
Benazepril Hcl	Benazepril Hcl	75	19
Clonazepam	Clonazepam	74	15
Baclofen	Baclofen	72	23
Ciprofloxacin Hcl	Ciprofloxacin Hcl	67	50
Hydralazine Hcl	Hydralazine Hcl	65	17
Fluticasone Propionate	Fluticasone Propionate	63	27
Albuterol Sulfate Hfa	Albuterol Sulfate	61	24
Diazepam	Diazepam	61	suppressed
Finasteride	Finasteride	60	15
Sertraline Hcl	Sertraline Hcl	59	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	56	16
Lorazepam	Lorazepam	55	11
Pregabalin	Pregabalin	54	11
Trulicity	Dulaglutide	54	suppressed
Citalopram Hbr	Citalopram Hydrobromide	53	suppressed
Diclofenac Sodium	Diclofenac Sodium	53	14
Doxycycline Hyclate	Doxycycline Hyclate	53	34
Montelukast Sodium	Montelukast Sodium	53	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	51	13
Fenofibrate	Fenofibrate,micronized	51	16
Trazodone Hcl	Trazodone Hcl	47	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	45	12
Methylprednisolone	Methylprednisolone	42	30
Warfarin Sodium	Warfarin Sodium	42	12
Glipizide	Glipizide	41	suppressed
Glipizide Er	Glipizide	41	14
Atenolol	Atenolol	40	11
Amitriptyline Hcl	Amitriptyline Hcl	39	suppressed
Cefdinir	Cefdinir	39	22
Celecoxib	Celecoxib	38	suppressed
Donepezil Hcl	Donepezil Hcl	36	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	36	11
Paroxetine Hcl	Paroxetine Hcl	36	suppressed
Bupropion Xl	Bupropion Hcl	33	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	12
Fenofibrate	Fenofibrate	33	suppressed
Valsartan	Valsartan	33	11
Irbesartan	Irbesartan	31	suppressed
Ozempic	Semaglutide	31	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	30	suppressed
Spironolactone	Spironolactone	30	suppressed
Dutasteride	Dutasteride	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	19
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	29	suppressed
Ezetimibe	Ezetimibe	28	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Nifedipine Er	Nifedipine	27	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Linzess	Linaclotide	26	suppressed
Meclizine Hcl	Meclizine Hcl	26	12
Azelastine Hcl	Azelastine Hcl	25	12
Januvia	Sitagliptin Phosphate	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Myrbetriq	Mirabegron	24	suppressed
Novolog Flexpen	Insulin Aspart	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	24	suppressed
Ondansetron Odt	Ondansetron	23	suppressed
Buspirone Hcl	Buspirone Hcl	22	suppressed
Famotidine	Famotidine	22	suppressed
Nadolol	Nadolol	22	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	21	suppressed
Enalapril Maleate	Enalapril Maleate	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	15
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	18	suppressed
Glimepiride	Glimepiride	18	suppressed
Primidone	Primidone	18	suppressed
Sucralfate	Sucralfate	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	13
Febuxostat	Febuxostat	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	17
Ramipril	Ramipril	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	14
Bumetanide	Bumetanide	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Nebivolol Hcl	Nebivolol Hcl	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	14	suppressed
Divalproex Sodium Er	Divalproex Sodium	13	suppressed
Premarin	Estrogens, Conjugated	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Topiramate	Topiramate	13	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	12	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Flecainide Acetate	Flecainide Acetate	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Niacin Er	Niacin	12	suppressed
Temazepam	Temazepam	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Clotrimazole	Clotrimazole	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Prednisone	Prednisone	11	suppressed
Repatha Sureclick	Evolocumab	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$81.56 · 4 records	Boston Scientific Corporation	WATCHMAN FLX, XIFAXAN, ZORYVE	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error